Pfizer Inc. Stock
€21.90
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and
5 Healthcare Plays Powering the Sector’s Big Comeback
After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However
Pfizer is Locking in New Growth Through a New Acquisition
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug
3 Long-Term Dividend Buys You Can Get for Under $50
Despite ongoing concerns about overvalued stocks, many value investors sleep well at night. That’s because the key to long-term value investing is total return, which includes a healthy, growing
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Today’s stock market focus is centered on one single sector: technology stocks.
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
Pfizer's (NYSE: PFE) shares have been southbound for the last three years. And unfortunately for the company, it doesn't look like things will improve significantly in 2026. The pharmaceutical
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks
Dividend stocks can be the ultimate investments to buy and forget about. They'll generate recurring income for your portfolio, even if you've forgotten you own them. What's important, however, is to
Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?
A rising tide doesn't lift all boats. For example, a boat with gaping holes in its hull will sink regardless of how high the tide rises. Pfizer (NYSE: PFE) seemed to be the investing equivalent of
3 Drug Stocks to Buy at a Discount
Over short periods, Wall Street is largely driven by emotions. When there's a compelling story, such as the emergence of GLP-1 weight loss drugs in the pharmaceutical sector, investors tend to
This Could Be Key to Pfizer's Turnaround in 2026
Did you know that in just the past three years, healthcare giant Pfizer (NYSE: PFE) has lost approximately half its value? The stock surged during the pandemic as its COVID-19 vaccine and pill
This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping)
The average blue chip dividend stock's current yield is somewhere in the ballpark of 3% to 4%. Therefore, to see one paying out nearly 7% of its value is as suspicious as it is impressive.
When the
Better Dividend Stock: Ford vs. Pfizer
Dividend stocks can be a good strategy for investors seeking a reliable and potentially more predictable stream of passive income. Two companies with high dividend yields are the longtime automaker
How Safe Is Pfizer's Dividend As 2026 Begins?
How many profitable, large-cap healthcare companies pay a dividend yield of over 5%? Only one.
Pfizer (NYSE: PFE) checks off all the boxes. It's profitable, raking in earnings of over $9.4 billion
2 Predictions for Pfizer in 2026
Is 2026 the year Pfizer (NYSE: PFE) finally turns things around? The company has been struggling over the past few years due to poor financial results and looming patent cliffs. However, it has also
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026?
The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine
3 Drug Stocks to Buy at a Discount
The pharmaceutical industry is highly technical, and significant developments can rapidly transform the sector. For instance, Novo Nordisk's (NYSE: NVO) introduction of GLP-1 weight loss drugs was a
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
Shares of Novo Nordisk (NYSE: NVO) surged after the company introduced its GLP-1 weight loss drugs to the market. Investors correctly recognized the desirability of a weight loss drug, but, as often
Better Buy in 2026: Pfizer or Merck?
Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a